Recently, significant progress has been made in the targeted therapy of CRC; the drugs targeting EGFR, PD-1/PD-L1, BRAF, CTLA-4, and NTRK have been approved to treat CRC patients and achieved great benefits4,5. This evidence concerns the gene BRAF and colorectal carcinoma.